Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07768124

Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Respiratory Tract Neoplasms Signs and Symptoms Signs and Symptoms, Digestive Thoracic Neoplasms Vomiting

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The Affiliated Yongchuan Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 402160, China

Location status: Recruiting

Location contact

Xiu HUANG

CONTACT

[email protected]

+8615023119040

About this study

Adults with pathologically confirmed lung cancer who are scheduled to receive first-line platinum-based chemotherapy are eligible. After providing written informed consent, participants are randomized 1:1 to receive either acupoint application using a herbal plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis, or 5-HT3 receptor antagonist prophylaxis alone. Nausea and vomiting episodes are recorded by participants using patient diaries, and quality of life is assessed with the Functional Living Index-Emesis questionnaire.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathologically or cytologically confirmed lung cancer.
  • Scheduled to receive first-line platinum-based chemotherapy.
  • Aged 18 to 75 years.
  • Karnofsky Performance Status (KPS) score ≥ 60.
  • Expected survival ≥ 3 months.
  • Voluntarily signed written informed consent.

Exclusion criteria

  • Known allergy to any component of the acupoint plaster.
  • Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
  • Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
  • Participation in another interventional clinical trial within 30 days prior to enrollment.

Treatment and study plan

5-HT3 receptor antagonist (e.g., ondansetron)

Drug

Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.

Acupoint application

Other

Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.

Primary outcomes

  1. Complete response rate of delayed-phase CINV (24-120 h)

    Time frame: 24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

    Complete response is defined as no emetic episodes and no rescue antiemetic use during 24 to 120 hours after the first cycle of platinum-based chemotherapy. The outcome will be compared between the acupoint application plus 5-HT3 receptor antagonist group and the 5-HT3 receptor antagonist alone group.

Secondary outcomes

  1. Complete response rate of acute-phase CINV (0-24 h)

    Time frame: 0 to 24 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

    Complete response is defined as no emetic episodes and no rescue antiemetic use during 0 to 24 hours after the first cycle of platinum-based chemotherapy.

  2. MAT nausea score

    Time frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

    Nausea severity measured by the Morrow Assessment of Nausea and Emesis (MAT) questionnaire after the first cycle of platinum-based chemotherapy.

  3. FLIE quality-of-life score

    Time frame: During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

    Quality of life assessed by the Functional Living Index-Emesis (FLIE) questionnaire after the first cycle of platinum-based chemotherapy.

Study contacts

Contact information is provided by the study sponsor or research team.

XIU HUANG

CONTACT

[email protected]

+8615023119040

Sponsors and collaborators

Lead sponsor

Xiu Huang

Other

Registry information

Official study title

Acupoint Application Combined With 5-HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: A Single-Center, Randomized, Controlled Trial

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 17, 2026
Registry last updated
Aug 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.